Tacrolimus and cardiotoxicity in adult liver transplant recipients

Dollinger, MM; Plevris, John; Chauhan, Anoop; MacGilchrist, Alastair; Finlayson, N.; Hayes, P.C.

doi:10.1016/s0140-6736(95)91357-2

Cited by 27 publications

(7 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In adults, various findings have been published. In one postmortem examination of patients on tacrolimus or cyclosporine therapy, hypertrophy of the heart was noted (26), whereas other reports have been negative (27). In our study, there were no obvious differences concerning Holter-ECG findings between the two different drugs for immunosuppression therapy.…”

Section: Long-term Follow-up (N‫)71؍‬contrasting

confidence: 62%

Liver Transplantation Does Not Prevent the Development of Life-Threatening Arrhythmia in Familial Amyloidotic Polyneuropathy, Portuguese-Type (ATTR Val30Met) Patients

et al. 2004

View full text Add to dashboard Cite

show abstract

Section: Long-term Follow-up (N‫)71؍‬contrasting

confidence: 62%

Liver Transplantation Does Not Prevent the Development of Life-Threatening Arrhythmia in Familial Amyloidotic Polyneuropathy, Portuguese-Type (ATTR Val30Met) Patients

et al. 2004

View full text Add to dashboard Cite

show abstract

“…It was hypothesized that perhaps tacrolimus does have a more adverse cardiac profile, although clinical events are relatively rare. Prior to this study, our group sought evidence of cardiotoxicity in our adult patients treated with tacrolimus 116. A total of 12 patients were studied and we found a variety of abnormalities on 2‐dimensional echocardiography.…”

Section: Cardiac Toxicity Associated With Immunosuppressionmentioning

confidence: 99%

Cardiac morbidity and mortality related to orthotopic liver transplantation

et al. 2004

View full text Add to dashboard Cite

“…Another study in adult patients performed by Dollinger et al 26 reported that four of 12 patients developed cardiac abnormalities (left ventricular hypertrophy) after undergoing liver transplantation with tacrolimus. All of the patients had tacrolimus levels targeted between 10 and 20 ng/ml.…”

Section: Discussionmentioning

confidence: 99%

Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD

Espino

Denney

Furlong

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:The incidence of myocardial hypertrophy was determined in a comparative study of tacrolimus-based immunosuppression with cyclosporine-based immunosuppression for prevention of acute graft-versus-host disease (GVHD) after unrelated donor bone marrow transplantation. Patients were evaluated for clinical and echocardiographic abnormalities at baseline (prior to pretreatment conditioning and the first dose of study drug) and at 5-8 weeks after transplant when stable levels of oral tacrolimus or cyclosporine had been achieved. Left ventricular geometry and performance were assessed by echocardiography which included 2-D measurements and one Doppler measurement. Derived echocardiographic measurements and left ventricular mass index (LVMI) were also determined. A cut-off of Ͻ111 g/m 2 was used for the upper limit of normal for LVMI. Forty-four patients were included in this study (21 tacrolimus and 23 cyclosporine), of which 31 were evaluable for a comparison with both baseline and posttransplant values. There was no significant difference in the changes from baseline for mean left ventricular mass (LVM) or LVM index (LVMI) between treatment groups. Also, within the tacrolimus group there were no significant changes for these variables from baseline to post-transplant evaluations. Within the cyclosporine group there were significant increases from baseline for mean LVM (P = 0.011) and LVMI (P = 0.007). The incidence of myocardial hypertrophy (change of LVMI from Ͻ111 g/m 2 baseline to Ͼ111 g/m 2 post transplant) was 20% in the tacrolimus group and 56% in the cyclosporine group (P = 0.109). Changes in the LVMI from baseline to post baseline were greater with cyclosporine than with tacrolimus therapy, and there was no evidence that tacrolimus causes myocardial hypertrophy or significant clinical changes in adult bone marrow transplant patients. The increase in LVMI after trans-

show abstract

Tacrolimus and cardiotoxicity in adult liver transplant recipients

Cited by 27 publications

References 1 publication

Liver Transplantation Does Not Prevent the Development of Life-Threatening Arrhythmia in Familial Amyloidotic Polyneuropathy, Portuguese-Type (ATTR Val30Met) Patients

Liver Transplantation Does Not Prevent the Development of Life-Threatening Arrhythmia in Familial Amyloidotic Polyneuropathy, Portuguese-Type (ATTR Val30Met) Patients

Cardiac morbidity and mortality related to orthotopic liver transplantation

Assessment of myocardial hypertrophy by echocardiography in adult patients receiving tacrolimus or cyclosporine therapy for prevention of acute GVHD

Contact Info

Product

Resources

About